$136.2 M

CTIC Mkt cap, 20-Jul-2018

$10.5 M

CTI BioPharma Revenue Q1, 2018
CTI BioPharma Net income (Q1, 2018)-4 M
CTI BioPharma EBIT (Q1, 2018)-4.3 M
CTI BioPharma Cash, 31-Mar-2018104.6 M
CTI BioPharma EV32.9 M

CTI BioPharma Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

34.7 m60.1 m16.1 m57.4 m25.1 m

Revenue growth, %

73%(73%)256%

Cost of goods sold

137 k895 k1.9 m1.4 m

Gross profit

34.5 m59.2 m14.2 m56 m

Gross profit Margin, %

100%99%88%98%

R&D expense

65 m32.9 m

General and administrative expense

45.3 m31.4 m

Operating expense total

110.3 m64.3 m

EBIT

(41.5 m)(86.2 m)(116.7 m)(49.2 m)(39.5 m)

EBIT margin, %

(120%)(144%)(724%)(86%)(157%)

Interest expense

1 m1.9 m2.1 m2.6 m1.9 m

Net Income

(43.6 m)(94.2 m)(120.8 m)(53 m)(45 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

362 k1.4 m1.3 m39.5 m2.7 m1.1 m964 k36.5 m7.4 m4.4 m754 k22.2 m10.5 m

R&D expense

7.2 m12.2 m14 m16.5 m17.5 m19.3 m18.4 m20.8 m16.7 m17.7 m9.3 m8.9 m9.7 m

General and administrative expense

8.5 m16.8 m13.8 m12.6 m12.3 m12.6 m13.7 m11.3 m9.6 m15.2 m10.7 m8 m5.4 m

Operating expense total

15.9 m29.1 m28 m32.1 m30.2 m32.1 m32.9 m32.3 m26.4 m33.1 m20.1 m17 m15.1 m

EBIT

(15.6 m)(27.7 m)(26.7 m)7.5 m(27.5 m)(31 m)(32 m)4.1 m(19.1 m)(28.7 m)(19.3 m)5.3 m(4.3 m)

EBIT margin, %

(4304%)(1961%)(1986%)19%(1007%)(2821%)(3315%)11%(259%)(647%)(2562%)24%(41%)

Interest expense

316 k464 k467 k472 k494 k597 k1.3 m714 k677 k634 k534 k488 k288 k

Net Income

(29 m)(27.4 m)(28.6 m)(32.6 m)(32.6 m)3.3 m(19.8 m)(29.2 m)(19.8 m)5.4 m(4 m)

CTI BioPharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6 m70.9 m128.2 m44 m27.2 m

Accounts Receivable

235 k2 m282 k378 k4 k

Inventories

3.6 m3.4 m3.7 m1.5 m550 k

Current Assets

80.5 m80.5 m135 m55.8 m46.9 m

PP&E

5.5 m4.6 m3.7 m3 m2.4 m

Total Assets

93.7 m92.3 m144.3 m63.8 m54.9 m

Accounts Payable

5.1 m6.4 m10.6 m7.2 m2.6 m

Short-term debt

3.2 m9 m37.4 m7.9 m444 k

Current Liabilities

20.1 m36.3 m72.4 m40.6 m19.3 m

Long-term debt

10.2 m8.4 m19.1 m11.3 m

Total Debt

13.3 m17.4 m56.5 m7.9 m444 k

Total Liabilities

56.1 m38.8 m

Retained Earnings

(1.9 b)(2 b)(2.1 b)(2.2 b)(2.2 b)

Total Equity

42.8 m38.5 m47.4 m7.8 m16.1 m

Debt to Equity Ratio

0.3 x0.5 x1.2 x1 x

Debt to Assets Ratio

0.1 x0.2 x0.4 x0.1 x

Financial Leverage

2.2 x2.4 x3 x8.2 x3.4 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

27.2 m50.6 m33.2 m29.9 m44.4 m54.9 m46.4 m104.6 m76.7 m61.6 m33.3 m74.7 m104.6 m

Accounts Receivable

540 k503 k613 k1.2 m1.3 m880 k422 k666 k559 k620 k311 k480 k

Inventories

3.7 m5 m5 m4.5 m3.6 m3.6 m2.6 m2.9 m2.6 m2.6 m1.5 m1.5 m564 k

Current Assets

33.7 m59.9 m42.3 m55.9 m53.5 m63.9 m53.3 m113.9 m88.9 m67.9 m36.8 m78.4 m107.8 m

PP&E

5.8 m5.1 m5 m4.8 m4.4 m4.1 m4 m3.6 m3.4 m3.2 m2.8 m2.6 m2.2 m

Total Assets

47.2 m73.3 m55.3 m68.6 m63.1 m73.5 m63.1 m123.4 m97.6 m76.5 m44.7 m86.3 m115.7 m

Accounts Payable

10.4 m4.6 m6.4 m6.3 m10.3 m11.2 m13.4 m17.7 m14 m13.7 m11.9 m4 m2.2 m

Short-term debt

1.2 m2.5 m4.2 m5.9 m9.3 m2.8 m4.3 m7.3 m7.5 m7.7 m8.2 m8.4 m1.3 m

Current Liabilities

20.5 m18.1 m23.8 m28.8 m35.4 m33.1 m36.5 m46.4 m40.8 m46.3 m41.9 m36.5 m20.2 m

Total Debt

1.2 m2.5 m4.2 m5.9 m9.3 m2.8 m4.3 m7.3 m7.5 m7.7 m8.2 m8.4 m1.3 m

Total Liabilities

33.4 m36.6 m40.7 m44.7 m48.7 m89 m90.6 m68.7 m60.9 m64 m55 m47.4 m38.7 m

Additional Paid-in Capital

2.3 b

Retained Earnings

(1.9 b)(1.9 b)(1.9 b)(1.9 b)(2 b)(2 b)(2.1 b)(2.1 b)(2.1 b)(2.1 b)(2.2 b)(2.2 b)(2.2 b)

Total Equity

387 k23.2 m6.7 m16 m14.1 m(15.5 m)(27.5 m)54.7 m36.8 m12.5 m38.9 m77 m

Financial Leverage

122.1 x3.2 x8.3 x4.3 x4.5 x-4.7 x-2.3 x2.3 x2.7 x6.1 x2.2 x1.5 x

CTI BioPharma Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(43.6 m)(94.2 m)(120.8 m)(53 m)

Depreciation and Amortization

1.6 m1.1 m990 k831 k717 k

Accounts Receivable

(227 k)(2 m)1.6 m(156 k)402 k

Inventories

4.5 m46 k(402 k)567 k1.1 m

Accounts Payable

(5.8 m)1.5 m4.4 m(3 m)(4.7 m)

Cash From Operating Activities

(35.8 m)(39.6 m)(95.2 m)(76.7 m)(39.3 m)

Purchases of PP&E

(1.7 m)(333 k)(78 k)(137 k)(49 k)

Cash From Investing Activities

(1.5 m)(541 k)(78 k)(137 k)(38 k)

Cash From Financing Activities

59 m36 m152 m(7.4 m)39 m

Interest Paid

933 k1.9 m2.1 m4.4 m2 m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(29 m)(27.4 m)(28.6 m)(32.6 m)(32.6 m)3.3 m(19.8 m)(29.2 m)(19.8 m)

Depreciation and Amortization

152 k

Accounts Receivable

613 k1.2 m1.3 m880 k422 k666 k559 k620 k311 k4 k

Inventories

5 m4.5 m3.6 m3.6 m

Accounts Payable

6.4 m6.3 m10.3 m11.2 m13.4 m17.7 m14 m13.7 m11.9 m(419 k)

Cash From Operating Activities

(2.4 m)

Purchases of PP&E

(33 k)

Cash From Investing Activities

(33 k)

Cash From Financing Activities

64.6 m

Interest Paid

284 k

CTI BioPharma Ratios

USDY, 2018

EV/EBIT

-7.6 x

EV/CFO

-13.6 x

Revenue/Employee

104.8 k

Financial Leverage

1.5 x
Report incorrect company information

CTI BioPharma Operating Metrics

FY, 2016

Phase III Trials Products

2
Report incorrect company information